Wang Juan, Xiang Ping, Zhou Shen, Yang Xin
Chongqing Preschool Education College, Wanzhou District, Chongqing, China.
Clinical Laboratory Center, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei, China.
Medicine (Baltimore). 2025 Aug 22;104(34):e43842. doi: 10.1097/MD.0000000000043842.
Metastatic head and neck tumors, especially metastatic head and neck squamous cell carcinoma, have a poor prognosis and are complex to treat. Although chemotherapy remains the standard first-line treatment option, it is often associated with tumor resistance and side effects. The aim of this retrospective cohort study was to evaluate the efficacy and safety of the combination of panitumumab and paclitaxel in the treatment of metastatic head and neck tumors. The study divided patients into experimental (panitumumab with paclitaxel + cisplatin treatment) and control (paclitaxel + cisplatin treatment) groups, with the primary assessment of objective remission rate and the secondary endpoints of disease control rate, progression-free survival (PFS), and overall survival (OS). The results of the study showed that there was no significant difference in short-term efficacy between the experimental group and the control group (P > .05), but the PFS (median value: 10.2 months) and OS (median value: 15.4 months) of the experimental group were significantly better than those of the control group (median value of PFS: 8.1 months, median value of OS: 11.8 months), and the difference was statistically significant (P < .001). The incidence of adverse events was higher in the experimental group than in the control group, especially in electrolyte disorders and skin rash, and the difference was statistically significant (P < .05), but most of these adverse events were tolerable. In conclusion, the combination of panitumumab and paclitaxel was associated with prolonged PFS and OS in patients with metastatic head and neck tumors, with manageable safety and tolerability compared to standard chemotherapy. These findings suggest that this regimen may represent a potential treatment option and warrant further validation in prospective, randomized studies.
转移性头颈部肿瘤，尤其是转移性头颈部鳞状细胞癌，预后较差且治疗复杂。尽管化疗仍是标准的一线治疗选择，但它常与肿瘤耐药性和副作用相关。这项回顾性队列研究的目的是评估帕尼单抗与紫杉醇联合治疗转移性头颈部肿瘤的疗效和安全性。该研究将患者分为试验组（帕尼单抗联合紫杉醇+顺铂治疗）和对照组（紫杉醇+顺铂治疗），主要评估客观缓解率，次要终点为疾病控制率、无进展生存期（PFS）和总生存期（OS）。研究结果显示，试验组和对照组的短期疗效无显著差异（P>0.05），但试验组的PFS（中位值：10.2个月）和OS（中位值：15.4个月）显著优于对照组（PFS中位值：8.1个月，OS中位值：11.8个月），差异具有统计学意义（P<0.001）。试验组不良事件的发生率高于对照组，尤其是电解质紊乱和皮疹，差异具有统计学意义（P<0.05），但这些不良事件大多可以耐受。总之，帕尼单抗与紫杉醇联合使用可延长转移性头颈部肿瘤患者的PFS和OS，与标准化疗相比，安全性和耐受性可控。这些发现表明，该治疗方案可能是一种潜在的治疗选择，值得在前瞻性随机研究中进一步验证。
